Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease
about
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseasePhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseaseThe cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory DiseasesA rational approach to single, dual and triple therapy in COPDCan roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysisPharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewDrug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma.β2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4DNo relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled studyExposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung.The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthmaInhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in ratsReduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.Inhibitory effects of Stemona tuberosa on lung inflammation in a subacute cigarette smoke-induced mouse modelCross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease.A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.Anti-inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus-inducible cytokinesUpdate in chronic obstructive pulmonary disease 2007.Treating patients with respiratory disease who smoke.Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD.PDE4 inhibitors: a review of current developments (2005 - 2009).Is there a role for antiinflammatory treatment in COPD?Targeting cancer with phosphodiesterase inhibitors.Effects of yoga in adults with type 2 diabetes mellitus: A meta-analysis.Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.Developments in drugs for the treatment of chronic obstructive pulmonary disease.Current perspectives of oxidative stress and its measurement in chronic obstructive pulmonary disease.Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseaseA new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD.Pharmacological treatment of COPD.Pharmacokinetic evaluation of roflumilast.Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.Roflumilast: a novel treatment for chronic obstructive pulmonary disease.Corticosteroid resistance and novel anti-inflammatory therapies in chronic obstructive pulmonary disease: current evidence and future direction.
P2860
Q24202545-1E66E4A5-F3C9-4394-91D7-510D9FF8F13CQ24234493-83BE348C-EB67-4109-96B4-BBAD01544581Q26750377-667B872A-C539-4458-BF27-559428FCE6AFQ26776477-5CB1F8F7-FA3B-45E2-B9DA-5E28A663837BQ28070108-C24E0985-1CE4-4A48-A6B8-692A3AA0C7A9Q28070274-46D8C39F-F4B5-46CE-B518-88ACFCAC8EB8Q30249747-8D45BA57-B609-4C1A-8BB6-C36A96C482FBQ33552229-A5329658-1F2B-455F-99F6-D6F9021C6342Q33624262-524E6752-594F-4B80-9DF5-1187E44CBBD2Q33737175-C9174F24-528E-4878-86AB-6B4B9BF9CCE4Q33911113-F9E531D1-1BDE-4669-B5FF-6B0793C631D5Q33919207-7A03AC05-BD46-431B-B702-64F01385654DQ34219585-984AC6E4-A9DD-4F31-A107-4763025CB539Q34491824-BA84309E-BBBA-4AB3-9D3E-7C6E251966CFQ34540209-C33EF8F6-843A-4D3D-B190-0924275C7B40Q34578865-9DAF2153-E55F-4030-A281-06296EDAEBC2Q35191277-95054CF6-973A-4258-8B96-05D58E5D563AQ35377816-04CB25C9-7F18-48AD-BF69-69E113D9B800Q35838660-69725C52-F977-44DB-8B22-A571333BF5D8Q35987189-714FE4B2-F93D-46D0-8086-9ED1388C0FD1Q36272434-BDE26908-8C3C-42C3-8F37-B3B3156EA9B4Q36648886-EE04E86F-D085-4C13-A9E5-AFB9335622F6Q37129292-7FDD058A-9498-4844-8382-CB2C61DB62CCQ37362600-FB80D22C-034A-4A12-86B3-430160D874CFQ37595806-DF04C0DC-AACB-4777-B1A3-3375A2AC94E3Q37615398-5D6B4603-88C1-45FF-9555-88EF3F9640F6Q37622935-2E96EAF7-7E69-4203-9AB5-E02A088DCA1AQ37650389-57012FDC-8337-4123-AC32-8FFC0E31A7B2Q37677880-05C35669-88D6-446A-974F-FB46E8D71606Q37681577-2989594B-0091-4746-BDD4-E6D754F070F2Q37732234-E8AFDE68-2D0B-48AF-AD54-52C354DF1D46Q37754541-7161987F-D8C3-4B13-B909-68CA39122AB0Q37776727-8A481263-B87A-487F-A174-57AE54E8A2B2Q37828179-73DC9392-78B6-404B-9841-E506D8271C9AQ37834142-93322CBA-6292-4CBA-AF30-EE63D34ECF0CQ37924598-093DCBD1-723C-4552-A717-D7348C2B1E4BQ37953446-B80F0804-19B3-4423-AE96-EA42448FFF23Q37992679-7589E36B-1046-46A2-BFC4-0294EF8783B8Q37995404-B5DF6E9B-7E41-4F10-A267-252803392240Q38021518-C2880A4F-BB9D-475C-BAEE-3D21033F53A2
P2860
Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease
description
im April 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 26 April 2007
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2007
@uk
name
Effect of 1-Year Treatment wit ...... Obstructive Pulmonary Disease
@en
Effect of 1-Year Treatment wit ...... Obstructive Pulmonary Disease
@nl
type
label
Effect of 1-Year Treatment wit ...... Obstructive Pulmonary Disease
@en
Effect of 1-Year Treatment wit ...... Obstructive Pulmonary Disease
@nl
prefLabel
Effect of 1-Year Treatment wit ...... Obstructive Pulmonary Disease
@en
Effect of 1-Year Treatment wit ...... Obstructive Pulmonary Disease
@nl
P2093
P2860
P1476
Effect of 1-year treatment wit ...... obstructive pulmonary disease
@en
P2093
Andrew McIvor
Dirk Bredenbroeker
Fernando Sanchez-Toril
Peter M A Calverley
Peter Teichmann
P2860
P304
P356
10.1164/RCCM.200610-1563OC
P407
P577
2007-04-26T00:00:00Z